Russian Heart Failure Journal 2005year Efficacy of therapy with the ACEI fosinopril in patients with CHF combined with type 2 DM (by data of FASON study)
Efficacy of therapy with the ACEI fosinopril in patients with CHF combined with type 2 DM (by data of FASON study)
Iljina A.V., Mareev V.Yu., Gerasimova V.V., Dzhakhangirov T.Sh., Belenkov Yu.N.
Urgency. According to data of the Russian epidemiological study «EPOCH», evaluation of relative contribution of different diseases to development of CHF showed that the presence of type 2 DM (NIDDM) was the third by significance cause of pronounced CHF after only AH and IHD. Aim. Analyzing the efficacy, safety and cost efficiency of using a current ACEI fosinopril for the treatment of CHF including CHF in combination with NIDDM, by data of the Russian multicenter study FASON. Materials and methods. The study FASON enrolled 1945 patients with II–III FC CHF including 771 patients with documented presence or absence of NIDDM. All patients received fosinopril. Evaluation of patients before and after the treatment included clinical examination, assessment of LV EF, 6-min test and quality of life. Cost of treatment was estimated for each patient. Results. The fosinopril treatment resulted in improvement of the clinical status, decrease in mean CHF FC, and increases in 6-min walking distance and LV EF. Patients with CHF and NIDDM more often preserved normal LV systolic function than patients without concurrent NIDDM.